已收盤 11-06 16:00:00 美东时间
+0.050
+0.10%
Satellos Bioscience Inc. will host a conference call and audio webcast on Nov. 6, 2026, at 8:00 a.m. ET to discuss updates on the clinical and regulatory strategy for its Phase 2 pediatric study, BASECAMP, for Duchenne muscular dystrophy (DMD). The call will feature remarks from Satellos' CEO Frank Gleeson and Chief Medical Officer Wildon Farwell, M.D. A live webcast with accompanying slides will be available on the company's website, with a repl...
11-05 21:32
Satellos Bioscience Inc. has formed a Scientific Advisory Board (SAB) with leading experts in stem cell biology, regenerative medicine, neuroscience, and small molecule chemistry to guide its research on regeneration, aging, and neurodegenerative biology. The SAB will help explore how cellular processes influence aging, neurodegeneration, and muscle diseases, expanding Satellos' understanding of regenerative biology. The company is currently deve...
10-27 11:00
Satellos Bioscience Inc. announced its participation in two upcoming investor conferences in November 2026: the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9 and the Jefferies Global Healthcare Conference in London on November 18-19. The company will also host one-on-one investor meetings at both events. Satellos, focused on developing treatments for degenerative muscle diseases, is advancing forazapadin, an AAK1 ...
10-21 11:00
KANSAS CITY, Mo., May 28, 2026 /PRNewswire/ -- American Century Investments, a $330 billion global asset manager*, expands its exchange traded fund (ETF) platform with the launch of American...
05-28 22:37